Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(NY:
MAIA
)
2.980
-0.020 (-0.67%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MAIA
< Previous
1
2
3
Next >
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
December 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
November 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
November 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology Announces $4 Million Registered Direct Offering
November 15, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 31, 2023
Via
ACCESSWIRE
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
October 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
October 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
October 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
October 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
October 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
October 03, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Repurchase Program
September 28, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
August 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
June 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
June 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology, Inc. Announces Closing of Public Offering
April 27, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
April 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
April 18, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at AACR Annual Meeting 2023
April 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.